tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
BeOne Medicines to sell royalty rights of Imdelltra to Royalty Pharma for $950M
PremiumThe FlyBeOne Medicines to sell royalty rights of Imdelltra to Royalty Pharma for $950M
8d ago
BeOne Medicines’ Brukinsa tablet formulation approved by European Commission
Premium
The Fly
BeOne Medicines’ Brukinsa tablet formulation approved by European Commission
12d ago
BeOne Medicines: Strong Financial Performance and Promising Pipeline Drive Buy Rating
Premium
Ratings
BeOne Medicines: Strong Financial Performance and Promising Pipeline Drive Buy Rating
25d ago
BeiGene’s Earnings Call Highlights Robust Growth and Market Leadership
PremiumCompany AnnouncementsBeiGene’s Earnings Call Highlights Robust Growth and Market Leadership
27d ago
BeOne Medicines: Strong Financial Performance and Promising Pipeline Justify Buy Rating and Increased Price Target
Premium
Ratings
BeOne Medicines: Strong Financial Performance and Promising Pipeline Justify Buy Rating and Increased Price Target
27d ago
BeOne Medicines narrows FY25 revenue view to $5.0B-$5.3B from $4.9B-$5.3B
Premium
The Fly
BeOne Medicines narrows FY25 revenue view to $5.0B-$5.3B from $4.9B-$5.3B
27d ago
BeOne Medicines price target raised to $349 from $311 at RBC Capital
PremiumThe FlyBeOne Medicines price target raised to $349 from $311 at RBC Capital
2M ago
BeOne announces EC approval of Tevimbra in combination with chemotherapy
Premium
The Fly
BeOne announces EC approval of Tevimbra in combination with chemotherapy
2M ago
Buy Rating for BeOne Medicines: Promising Developments and Strategic Positioning
Premium
Ratings
Buy Rating for BeOne Medicines: Promising Developments and Strategic Positioning
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100